Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography
- PMID: 10931457
- DOI: 10.1002/1097-0142(20000801)89:3<582::aid-cncr13>3.0.co;2-#
Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography
Abstract
Background: International Federation of Gynecology and Obstetrics Stage I ovarian carcinoma, which has the worst prognosis among all types of gynecologic carcinoma, has a high cure rate as has been reported, but early diagnosis is difficult and to the authors' knowledge screening methods have not been established. Since 1989, the authors have performed transvaginal ultrasonography (TVS) as a form of screening for ovarian carcinoma. The purpose of the current study was to summarize and evaluate screening results for the last 10 years with respect to ovarian carcinoma diagnosis and risk factors.
Methods: Primary screening by TVS was performed in asymptomatic women who participated in annual uterine cervical carcinoma screening. Four scanning sections by TVS were established and all sonograms were recorded. Women with abnormal sonograms (a mass > 30 mm in greatest dimension or a mass with a mixed pattern) received secondary screening and closer examination with a tumor marker and an imaging diagnostic examination. Laparotomy was conducted on all masses with a greatest dimension of >/= 60 mm or on suspected malignant masses. Subject information-related risk factors also were recorded.
Results: Subjects were 183,034 women who participated in primary screening. Of these women, 51,550 were undergoing screening for the first time. The time required for primary screening was 1 minute per subject. Secondary screening was required for 5309 participants (10.3%) and surgery was performed on 324 participants. Twenty-two primary tumors and 2 metastatic tumors were detected for a diagnostic rate of 0.047%. Of the 22 primary tumors, 17 (77.3%) were classified as Stage I carcinoma, with tumor markers positive only for 5 (29.4%). The percentage of the total number of Stage I ovarian carcinoma cases increased after the induction of screening from 29.7% to 58.8%.
Conclusions: These results are significant in that 77.3% of the primary ovarian carcinomas found during the current screening were of curable Stage I. Increased use of TVS screening for ovarian carcinoma may increase the chance for early diagnosis and decrease the mortality of the disease.
Copyright 2000 American Cancer Society.
Similar articles
-
The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer.Gynecol Oncol. 2000 Jun;77(3):350-6. doi: 10.1006/gyno.2000.5816. Gynecol Oncol. 2000. PMID: 10831341 Clinical Trial.
-
Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened.Cancer. 2007 May 1;109(9):1887-96. doi: 10.1002/cncr.22594. Cancer. 2007. PMID: 17373668 Clinical Trial.
-
Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system.J Clin Oncol. 2005 Aug 20;23(24):5588-96. doi: 10.1200/JCO.2005.05.097. J Clin Oncol. 2005. PMID: 16110018
-
Ovarian cancer screening.Cancer. 1995 Nov 15;76(10 Suppl):2086-91. doi: 10.1002/1097-0142(19951115)76:10+<2086::aid-cncr2820761330>3.0.co;2-l. Cancer. 1995. PMID: 8635005 Review.
-
[The role of transvaginal ultrasonography in the screening of ovarian tumors].Minerva Ginecol. 1997 Jun;49(6):243-9. Minerva Ginecol. 1997. PMID: 9289662 Review. Italian.
Cited by
-
Screening for ovarian cancer: recommendation statement.Ann Fam Med. 2004 May-Jun;2(3):260-2. doi: 10.1370/afm.200. Ann Fam Med. 2004. PMID: 15209204 Free PMC article. No abstract available.
-
Potential markers for detection and monitoring of ovarian cancer.J Oncol. 2011;2011:475983. doi: 10.1155/2011/475983. Epub 2011 Apr 11. J Oncol. 2011. PMID: 21577260 Free PMC article.
-
Advantages and Limitations of Ultrasound as a Screening Test for Ovarian Cancer.Diagnostics (Basel). 2023 Jun 15;13(12):2078. doi: 10.3390/diagnostics13122078. Diagnostics (Basel). 2023. PMID: 37370973 Free PMC article. Review.
-
fTwo novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma.Expert Opin Med Diagn. 2011 May 1;5(3):227-240. doi: 10.1517/17530059.2011.559459. Expert Opin Med Diagn. 2011. PMID: 21643459 Free PMC article.
-
Molecular signatures of ovarian cancer: from detection to prognosis.Mol Diagn Ther. 2010 Feb 1;14(1):13-22. doi: 10.1007/BF03256349. Mol Diagn Ther. 2010. PMID: 20121286 Review.
MeSH terms
LinkOut - more resources
Other Literature Sources
Medical